| Literature DB >> 33680715 |
Serap Yalçın1, Seda Yalçınkaya2, Fahriye Ercan3.
Abstract
The novel human coronavirus was firstly emerged in December 2019 in Wuhan, China, and has spread rapidly around the world. There is no known specific effective treatment of COVID-19. The most commonly used agents against this disease both in Turkey and around the world include chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir, and remdesivir. In the study, we investigated the drug potential of molecules that the components of an important medicinal plant Hypericum perforatum by using molecular docking and drug possibility properties of these molecules. The molecular docking results showed that the most stable complex was obtained with COVID-19 main protease and hypericin/isohypericin ligands with - 11 kcal/mol binding energy. Furthermore, ADMET, drug-likeness features of compounds of H. perforatum were investigated using the rules of Lipinski, Veber, and Ghose. According to the results obtained, it has been shown that H. perforatum has the potential to be an effective drug in the COVID-19 pandemic. In the next stage, it is necessary to carry out the clinically necessary reliability studies of these components. It is thought that it can be used for the treatment of COVID-19 if our molecular docking results are found to be in high correlation with clinical studies. Supplementary Information: The online version contains supplementary material available at 10.1007/s40495-021-00254-9.Entities:
Keywords: ADMET; COVID-19; Drug-likeness drug; Hypericum perforatum; Molecular docking
Year: 2021 PMID: 33680715 PMCID: PMC7921287 DOI: 10.1007/s40495-021-00254-9
Source DB: PubMed Journal: Curr Pharmacol Rep ISSN: 2198-641X
Ligands used in the study and their properties
Target protein and drug candidate molecules (ligands) molecular docking results
| Ligands | Binding energy (kcal/mol) | H bound and a.a. side |
|---|---|---|
| Chloroquine | − 5.6 kcal/mol | 1 (Trp 218) |
| Hydroxychloroquine | − 7.0 kcal/mol | 0 |
| Hypericin | − 11 kcal/mol | 6 (Asp 197x2; Lys 137; Leu 287x3) |
| Protopseudohypericin | − 9.9 kcal/mol | 5 (Tyr 239x2; Leu 271, Leu 272; Thr 199) |
| Hyperocide | − 9.5 kcal/mol | 5 (Asn274; Glu 270; Arg 279; Asn 277x2) |
| Cryptochlorogenic acid | − 8.1 kcal/mol | 6 (Gly 183; Phe 181; Arg 188; Glu 55; Arg 40x2) |
| Isohypericin | − 11.0 kcal/mol | 4 (Asp 197x2; Lys 137; Tyr 239) |
| Mangiferin | − 9.7 kcal/mol | 6 (Thr 199; Asp 289; Leu 287; Tyr 239x2; Leu 271) |
| Neochlorogenic acid | − 8.6 kcal/mol | 2 (Thr 292; Thr 111) |
| Catechin | − 7.4 kcal/mol | 4 (Leu 287; Thr 199; Asp 197; Tyr 237) |
| Protocatehuic acid | − 5.9 kcal/mol | 4 (Asn 277x2; Arg 279; Asn 221) |
| 2-Methyldecane | − 5.0 kcal/mol | 0 |
| Pseudohypericin | − 10.7 kcal/mol | 5(Thr 199, Tyr 237, Leu 272, Leu 287x2) |
| Protohypericin | − 9.7 kcal/mol | 5 (Asn 238; Thr 199; Tyr 239x2; Leu 271; Leu 272) |
| Adhyperforin | − 8.8 kcal/mol | 1 (Leu 287) |
| Hiperforine | − 7.9 kcal/mol | 2 (Arg 279; Asn 274) |
| Miquelianin | − 9.8 kcal/mol | 3 (Tyr 239; Leu 287; Thr 199) |
| Biapigenin | − 9.8 kcal/mol | 6 (Leu 271; Leu 287x2; Tyr 239; Thr 199; Asn 238) |
| Guaijaverin | − 9.3 kcal/mol | 5 (Asn 274; Glu 270; Arg 279; Asn 277x2) |
| Epicatechin | − 7.9 kcal/mol | 5 (Tyr 237; Thr 199; Asp 289; Lys 137;Tyr 239) |
| Norathyriol | − 7.1 kcal/mol | 3 (Arg 105; Gln 110; Thr 111) |
| Beta-Ocimene | − 5.2 kcal/mol | 0 |
| 2-Methyloctane | − 4.3 kcal/mol | 0 |
Drug-likeness results of compounds
| Ligand | Drug-likeness | Bioavailability score | ||
|---|---|---|---|---|
| Lipinski | Ghose | Veber | ||
| Hypericin | No; 2 violations: MW > 500, NHorOH > 5 | No; 3 violations: MW > 480, WLOGP > 5.6, MR > 130 | No; 1 violation: TPSA > 140 | 0,17 |
| Pseudohypericin | No; 2 violations: MW > 500, NHorOH > 5 | No; 2 violations: MW > 480, MR > 130 | No; 1 violation: TPSA > 140 | 0,17 |
| Protopseudohypericin | No; 2 violations: MW > 500, NHorOH > 5 | No; 2 violations: MW > 480, MR > 130 | No; 1 violation: TPSA > 140 | 0,17 |
| Protohypericin | No; 2 violations: MW > 500, NHorOH > 5 | No; 2 violations: MW > 480, MR > 130 | No; 1 violation: TPSA > 140 | 0,17 |
| Hyperocide | No; 2 violations: NorO > 10, NHorOH > 5 | No; 1 violation: WLOGP < − 0.4 | No; 1 violation: TPSA > 140 | 0,17 |
| Adhyperforin | No; 2 violations: MW > 500, MLOGP > 4.15 | No; 4 violations: MW > 480, WLOGP > 5.6, MR > 130, #atoms > 70 | No; 1 violation: rotors > 10 | 0,56 |
| Cryptochlorogenic acid | Yes; 1 violation: NHorOH > 5 | No; 1 violation: WLOGP < − 0.4 | No; 1 violation: TPSA > 140 | 0,11 |
| Hiperforine | No; 2 violations: MW > 500, MLOGP > 4.15 | No; 4 violations: MW > 480, WLOGP > 5.6, MR > 130, #atoms > 70 | No; 1 violation: rotors > 10 | 0,56 |
| Isohypericin | No; 2 violations: MW > 500, NHorOH > 5 | No; 3 violations: MW > 480, WLOGP > 5.6, MR > 130 | No; 1 violation: TPSA > 140 | 0,17 |
| Miquelianin | No; 2 violations: NorO>10, NHorOH>5 | No; 1 violation: WLOGP < − 0.4 | No; 1 violation: TPSA > 140 | 0,11 |
| Biapigenin | No; 2 violations: MW > 500, NHorOH > 5 | No; 2 violations: MW > 480, MR > 130 | No; 1 violation: TPSA > 140 | 0,17 |
| Mangiferin | No; 2 violations: NorO > 10, NHorOH > 5 | No; 1 violation: WLOGP < − 0.4 | No; 1 violation: TPSA > 140 | 0,17 |
| Guaijaverin | No; 2 violations: NorO > 10, NHorOH > 5 | Yes | No; 1 violation: TPSA > 140 | 0,17 |
| Neochlorogenic acid | Yes; 1 violation: NHorOH > 5 | No; 1 violation: WLOGP < − 0.4 | No; 1 violation: TPSA > 140 | 0,11 |
| Epicatechin | Yes | Yes | Yes | 0,55 |
| Catechin | Yes | Yes | Yes | 0,55 |
| Norathyriol | Yes | Yes | Yes | 0,55 |
| Protocatehuic acid | Yes | No; 3 violations: MW<160, MR<40, #atoms < 20 | Yes | 0,56 |
| Beta-Ocimene | Yes | No; 1 violation: MW < 160 | Yes | 0,55 |
| 2-Methyldecane | Yes; 1 violation: MLOGP > 4.15 | No; 1 violation: MW < 160 | Yes | 0,55 |
| 2-Methyloctane | Yes; 1 violation: MLOGP > 4.15 | No; 1 violation: MW < 160 | Yes | 0,55 |